Menarini Stemline Revenue and Competitors

NY USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Menarini Stemline's estimated annual revenue is currently $92.8M per year.(i)
  • Menarini Stemline's estimated revenue per employee is $155,000

Employee Data

  • Menarini Stemline has 599 Employees.(i)
  • Menarini Stemline grew their employee count by 25% last year.

Menarini Stemline's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
COOReveal Email/Phone
3
VP, Global Head Medical Affairs, Hematology, Stemline TherapeuticsReveal Email/Phone
4
AVP, Commercial ExcellenceReveal Email/Phone
5
Sr. VP Quality OperationsReveal Email/Phone
6
Associate VP, US Biomarker / Companion Diagnostics StrategyReveal Email/Phone
7
Executive Assistant to SVP, Global Regulatory Affairs, Drug Safety, Pharmacovigilance & R&D QAReveal Email/Phone
8
Head HR - EuropeReveal Email/Phone
9
VP General Manager DACHReveal Email/Phone
10
Regional Marketing DirectorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-20%N/AN/A
#2
$6.7M438%N/AN/A
#3
$34.4M222-1%N/AN/A
#4
$5.2M670%$10MN/A
#5
$2M130%N/AN/A
#6
$7.5M370%$51.6MN/A
#7
$0.3M2-50%N/AN/A
#8
$4.3M21-16%$3.3MN/A
#9
$3.6M230%N/AN/A
#10
$4.3M56-8%$118MN/A
Add Company

What Is Menarini Stemline?

The Menarini Group ("Menarini"), a leading Italian pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to people living with cancer. Inspired by the goal to improve outcomes for those with unmet medical needs, Menarini Stemline is driven to discover and develop innovative therapeutics for the treatment of cancer. Netiquette & Privacy Notice

keywords:N/A

N/A

Total Funding

599

Number of Employees

$92.8M

Revenue (est)

25%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$164.7M5994%N/A
#2
$15M59965%N/A
#3
$151.2M5994%N/A
#4
$202.2M59971%N/A
#5
$160M600-18%$1.7B